Drug Repurposing in Crohn’s Disease Using Danish Real-World Data

References

• Pushpakom S, Iorio F, Eyers PA, et al. Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov. 2019;18(1):41–58. doi:10.1038/nrd.2018.168
   PubMed Web of Science ®Google Scholar
• Scannell JW, Blanckley A, Boldon H, Warrington B. Diagnosing the decline in pharmaceutical R&D efficiency. Nat Rev Drug Discov. 2012;11(3):191–200. doi:10.1038/nrd3681
   PubMed Web of Science ®Google Scholar
• Zanello G, Chan CH, Pearce DA, Group IrdW. Recommendations from the IRDiRC Working Group on methodologies to assess the impact of diagnoses and therapies on rare disease patients. Orphanet J Rare Dis. 2022;17(1):181. doi:10.1186/s13023-022-02337-2
   PubMed Web of Science ®Google Scholar
• Lin SN, Mao R, Qian C, et al. Development of antifibrotic therapy for stricturing Crohn’s disease: lessons from randomized trials in other fibrotic diseases. Physiol Rev. 2022;102(2):605–652. doi:10.1152/physrev.00005.2021
   PubMed Web of Science ®Google Scholar
• Ismail MS, Charabaty A. Management of Crohn’s stricture: medical, endoscopic and surgical therapies. Frontline Gastroenterol. 2022;13(6):524–530. doi:10.1136/flgastro-2021-101827
   PubMed Web of Science ®Google Scholar
• Alastruey CL, Murcia XA, Comas ME. The role of stents in the treatment of Crohn’s disease strictures. Endosc Int Open. 2016;4(03):E301–E308. doi:10.1055/s-0042-101786
   PubMedGoogle Scholar
• Sessa M, Mascolo A, Andersen MP, et al. Effect of chronic kidney diseases on mortality among digoxin users treated for non-valvular atrial fibrillation: a nationwide register-based retrospective cohort study. PLoS One. 2016;11(7):e0160337. doi:10.1371/journal.pone.0160337
   PubMed Web of Science ®Google Scholar
• Hagengaard L, Søgaard P, Espersen M, et al. Association between serum potassium levels and short-term mortality in patients with atrial fibrillation or flutter co-treated with diuretics and rate-or rhythm-controlling drugs. Eur Heart J. 2020;6(3):137–144. doi:10.1093/ehjcvp/pvz024
   Web of Science ®Google Scholar
• Sessa M, Khan AR, Liang D, Andersen M, Kulahci M. Artificial intelligence in pharmacoepidemiology: a systematic review. Part 1—overview of knowledge discovery techniques in artificial intelligence. Front Pharmacol. 2020;11:1028. doi:10.3389/fphar.2020.01028
   PubMed Web of Science ®Google Scholar
• Schmidt M, Pedersen L, Sørensen HT. The Danish Civil Registration System as a tool in epidemiology. Eur J Epidemiol. 2014;29(8):541–549. doi:10.1007/s10654-014-9930-3
   PubMed Web of Science ®Google Scholar
• Lynge E, Sandegaard JL, Rebolj M. The Danish national patient register. Scand J Public Health. 2011;39(7_suppl):30–33. doi:10.1177/1403494811401482
   PubMed Web of Science ®Google Scholar
• Kildemoes HW, Sørensen HT, Hallas J. The Danish national prescription registry. Scand J Public Health Suppl. 2011;39(7_suppl):38–41. doi:10.1177/1403494810394717
   Google Scholar
• Helweg-Larsen K. The Danish register of causes of death. Scand J Public Health. 2011;39(7_suppl):26–29. doi:10.1177/1403494811399958
   PubMed Web of Science ®Google Scholar
• Albaek Jacobsen H, Jess T, Larsen L. Validity of inflammatory bowel disease diagnoses in the Danish National Patient Registry: a population-based study from the North Denmark region. Clin Epidemiol. 2022;1099–1109. doi:10.2147/CLEP.S378003
   PubMed Web of Science ®Google Scholar
• Agrawal M, Ebert AC, Poulsen G, et al. Early ileocecal resection for Crohn’s disease is associated with improved long-term outcomes compared to anti-tumor necrosis factor therapy: a population-based cohort study. Gastroenterology. 2023;165(4):976–985.e3. doi:10.1053/j.gastro.2023.05.051
   PubMed Web of Science ®Google Scholar
• Kuhn M, Johnson K. Applied Predictive Modeling. Vol. 26. Springer; 2013.
   Google Scholar
• Schneeweiss S, Rassen JA, Glynn RJ, Avorn J, Mogun H, Brookhart MA. High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology. 2009;20(4):512. doi:10.1097/EDE.0b013e3181a663cc
   PubMed Web of Science ®Google Scholar
• Xue X, Xie X, Gunter M, et al. Testing the proportional hazards assumption in case-cohort analysis. BMC Med Res Methodol. 2013;13(1):1–10. doi:10.1186/1471-2288-13-88
   PubMedGoogle Scholar
• Horwitz RI, Feinstein AR. The problem of “protopathic bias” in case-control studies. Am J Med. 1980;68(2):255–258. doi:10.1016/0002-9343(80)90363-0
   PubMed Web of Science ®Google Scholar
• Wang Y, Huang B, Jin T, Ocansey DKW, Jiang J, Mao F. Intestinal Fibrosis in Inflammatory Bowel Disease and the Prospects of Mesenchymal Stem Cell Therapy. Front Immunol. 2022;13:835005. doi:10.3389/FIMMU.2022.835005/BIBTEX
   PubMed Web of Science ®Google Scholar
• Iwata K, Mikami Y, Kato M, Yahagi N, Kanai T. Pathogenesis and management of gastrointestinal inflammation and fibrosis: from inflammatory bowel diseases to endoscopic surgery. Inflamm Regen. 2021;41(1):1–8. doi:10.1186/S41232-021-00174-7/FIGURES/2
   PubMed Web of Science ®Google Scholar
• Rieder F. Managing Intestinal Fibrosis in Patients With Inflammatory Bowel Disease. Gastroenterol Hepatol. 2018;14(2):120.
   Google Scholar
• Sado A, Kalla R, Campbell S. Conventional and Future Therapies for Crohn’s Disease. OBM Hepatol Gastroenterol. 2019;3(3):1–19. doi:10.21926/obm.hg.1903032
   Google Scholar
• Scribano ML, Prantera C. Use of antibiotics in the treatment of Crohn’s disease. World J Gastroenterol. 2013;19(5):648. doi:10.3748/wjg.v19.i5.648
   PubMed Web of Science ®Google Scholar
• Barkas F, Liberopoulos E, Kei A, Elisaf M. Electrolyte and acid-base disorders in inflammatory bowel disease. Ann Gastroenterol. 2013;26(1):23.
   PubMedGoogle Scholar
• Rieder F, Fiocchi C, Rogler G. Mechanisms, management, and treatment of fibrosis in patients with inflammatory bowel diseases. Gastroenterology. 2017;152(2):340–350. doi:10.1053/j.gastro.2016.09.047
   PubMed Web of Science ®Google Scholar
• Klopcic B, Appelbee A, Raye W, et al. Indomethacin and retinoic acid modify mouse intestinal inflammation and fibrosis: a role for SPARC. Dig Dis Sci. 2008;53(6):1553–1563. doi:10.1007/s10620-007-0068-y
   PubMed Web of Science ®Google Scholar
• Kuźnicki P, Kempiński R, Neubauer K. The emerging role of mood disorders in inflammatory bowel diseases. Adv Clin Exp Med. 2020;29(12):1505–1510. doi:10.17219/acem/127676
   PubMed Web of Science ®Google Scholar
• Gao X, Tang Y, Lei N, et al. Symptoms of anxiety/depression is associated with more aggressive inflammatory bowel disease. Sci Rep. 2021;11(1):1440. doi:10.1038/s41598-021-81213-8
   PubMed Web of Science ®Google Scholar
• Mikocka-Walus A, Knowles SR, Keefer L, Graff L. Controversies revisited: a systematic review of the comorbidity of depression and anxiety with inflammatory bowel diseases. Inflamm Bowel Dis. 2016;22(3):752–762. doi:10.1097/MIB.0000000000000620
   PubMed Web of Science ®Google Scholar
• Kochar B, Barnes EL, Long MD, et al. Depression is associated with more aggressive inflammatory bowel disease. Am J Gastroenterol. 2018;113(1):80. doi:10.1038/ajg.2017.423
   PubMed Web of Science ®Google Scholar
• Uemura R, Fujiwara Y, Iwakura N, et al. Sleep disturbances in Japanese patients with inflammatory bowel disease and their impact on disease flare. Springerplus. 2016;5(1):1–8. doi:10.1186/s40064-016-3408-6
   PubMedGoogle Scholar
• Ananthakrishnan AN, Long MD, Martin CF, Sandler RS, Kappelman MD. Sleep disturbance and risk of active disease in patients with Crohn’s disease and ulcerative colitis. Clin Gastroenterol Hepatol. 2013;11(8):965–971. doi:10.1016/j.cgh.2013.01.021
   PubMed Web of Science ®Google Scholar
• Sofia MA, Lipowska AM, Zmeter N, Perez E, Kavitt R, Rubin DT. Poor sleep quality in Crohn’s disease is associated with disease activity and risk for hospitalization or surgery. Inflamm Bowel Dis. 2020;26(8):1251–1259. doi:10.1093/ibd/izz258
   PubMed Web of Science ®Google Scholar
• Kristensen MS, Kjærulff TM, Ersbøll AK, Green A, Hallas J, Thygesen LC. The influence of antidepressants on the disease course among patients with Crohn’s disease and ulcerative colitis—a Danish nationwide register–based Cohort Study. Inflamm Bowel Dis. 2019;25(5):886–893. doi:10.1093/ibd/izy367
   PubMed Web of Science ®Google Scholar
• Salmenkari H, Korpela R, Vapaatalo H. Renin–angiotensin system in intestinal inflammation—Angiotensin inhibitors to treat inflammatory bowel diseases? Basic Clin Pharmacol Toxicol. 2021;129(3):161–172. doi:10.1111/bcpt.13624
   PubMed Web of Science ®Google Scholar
• Jacobs JD, Wagner T, Gulotta G, et al. Impact of angiotensin II signaling blockade on clinical outcomes in patients with inflammatory bowel disease. Dig Dis Sci. 2019;64(7):1938–1944. doi:10.1007/s10620-019-5474-4
   PubMed Web of Science ®Google Scholar
• Fairbrass KM, Hoshen D, Gracie DJ, Ford AC. Effect of ACE inhibitors and angiotensin II receptor blockers on disease outcomes in inflammatory bowel disease. Gut. 2021;70(1):218–219. doi:10.1136/gutjnl-2020-321186
   PubMed Web of Science ®Google Scholar
• Cohn HM, Dave M, Loftus JEV. Understanding the cautions and contraindications of immunomodulator and biologic therapies for use in inflammatory bowel disease. Inflamm Bowel Dis. 2017;23(8):1301–1315. doi:10.1097/MIB.0000000000001199
   PubMed Web of Science ®Google Scholar
• Lysaa RA, Giverhaug T, Libæk Wold H, Aarbakke J. Inhibition of human thiopurine methyltransferase by furosemide, bendroflumethiazide and trichlormethiazide. Eur J Clin Pharmacol. 1996;49(5):393–396. doi:10.1007/BF00203784
   PubMed Web of Science ®Google Scholar
• Xin HW, Fischer C, Schwab M, Klotz U. Thiopurine S-methyltransferase as a target for drug interactions. Eur J Clin Pharmacol. 2005;61(5–6):395–398. doi:10.1007/s00228-005-0950-5
   PubMed Web of Science ®Google Scholar
• Khalili H, Higuchi LM, Ananthakrishnan AN, et al. Oral contraceptives, reproductive factors and risk of inflammatory bowel disease. Gut. 2013;62(8):1153–1159. doi:10.1136/gutjnl-2012-302362
   PubMed Web of Science ®Google Scholar
• Pasvol TJ, Bloom S, Segal AW, Rait G, Horsfall L. Use of contraceptives and risk of inflammatory bowel disease: a nested case–control study. Aliment Pharmacol Ther. 2022;55(3):318–326. doi:10.1111/apt.16647
   PubMed Web of Science ®Google Scholar
• Khalili H, Granath F, Smedby KE, et al. Association between long-term oral contraceptive use and risk of Crohn’s disease complications in a nationwide study. Gastroenterology. 2016;150(7):1561–1567. doi:10.1053/j.gastro.2016.02.041
   PubMed Web of Science ®Google Scholar
• Wanchaitanawong W, Thinrungroj N, Chattipakorn SC, Chattipakorn N, Shinlapawittayatorn K. Repurposing metformin as a potential treatment for inflammatory bowel disease: evidence from cell to the clinic. Int Immunopharmacol. 2022;112:109230. doi:10.1016/j.intimp.2022.109230
   PubMed Web of Science ®Google Scholar
• Azuma K, Osaki T, Kurozumi S, et al. Anti-inflammatory effects of orally administered glucosamine oligomer in an experimental model of inflammatory bowel disease. Carbohydr Polym. 2015;115:448–456. doi:10.1016/j.carbpol.2014.09.012
   PubMed Web of Science ®Google Scholar
• Salvatore S, Heuschkel R, Tomlin S, et al. A pilot study of N‐acetyl glucosamine, a nutritional substrate for glycosaminoglycan synthesis, in paediatric chronic inflammatory bowel disease. Aliment Pharmacol Ther. 2000;14(12):1567–1579. doi:10.1046/j.1365-2036.2000.00883.x
   PubMed Web of Science ®Google Scholar
• Patel SH, Rachchh MA, Jadav PD. Evaluation of anti-inflammatory effect of anti-platelet agent-clopidogrel in experimentally induced inflammatory bowel disease. Indian J Pharmacol. 2012;44(6):744. doi:10.4103/0253-7613.103278
   PubMed Web of Science ®Google Scholar
• Ibrahim SH, Smyrk TC, Faubion WA. Treatment of isolated gastric Crohn’s disease with inhaled corticosteroids. Case Rep Gastroenterol. 2008;2(3):363–368. doi:10.1159/000158543
   PubMedGoogle Scholar
• de Kaski MC, Peters AM, Lavender JP, Hodgson HJ. Fluticasone propionate in Crohn’s disease. Gut. 1991;32(6):657–661. doi:10.1136/gut.32.6.657
   PubMed Web of Science ®Google Scholar
• Prantera C, Marconi S. Glucocorticosteroids in the treatment of inflammatory bowel disease and approaches to minimizing systemic activity. Therap Adv Gastroenterol. 2013;6(2):137–156. doi:10.1177/1756283X12473675
   PubMed Web of Science ®Google Scholar
• Ghorbanzadeh B, Behmanesh MA, Mahmoudinejad R, Zamaniyan M, Ekhtiar S, Paridar Y. The effect of montelukast, a leukotriene receptor antagonist, on the acetic acid-induced model of colitis in rats: involvement of NO-cGMP-KATP channels pathway. Front Pharmacol. 2022;13:1011141. doi:10.3389/fphar.2022.1011141
   PubMed Web of Science ®Google Scholar
• Xie H, He SH. Roles of histamine and its receptors in allergic and inflammatory bowel diseases. World J Gastroenterol. 2005;11(19):2851. doi:10.3748/wjg.v11.i19.2851
   PubMed Web of Science ®Google Scholar
• Zhao X, Liu R, Chen Y, Hettinghouse A, Liu C. Cytosolic Phospholipase A2 Is Required for Fexofenadine’s Therapeutic Effects against Inflammatory Bowel Disease in Mice. Int J Mol Sci. 2021;22(20):11155. doi:10.3390/ijms222011155
   PubMed Web of Science ®Google Scholar
• Dvornikova KA, Platonova ON, Bystrova EY. Inflammatory Bowel Disease: crosstalk between Histamine, Immunity, and Disease. Int J Mol Sci. 2023;24(12):9937.
   PubMed Web of Science ®Google Scholar
• Chi F, Zhang G, Ren N, et al. The anti-alcoholism drug disulfiram effectively ameliorates ulcerative colitis through suppressing oxidative stresses-associated pyroptotic cell death and cellular inflammation in colonic cells. Int Immunopharmacol. 2022;111:109117. doi:10.1016/j.intimp.2022.109117
   PubMed Web of Science ®Google Scholar
• Zhou W, Zhang H, Huang L, et al. Disulfiram with Cu2+ alleviates dextran sulfate sodium-induced ulcerative colitis in mice. Theranostics. 2023;13(9):2879. doi:10.7150/thno.81571
   PubMed Web of Science ®Google Scholar
• Guo W, Chen S, Li C, Xu J, Wang L. Application of disulfiram and its metabolites in treatment of inflammatory disorders. Front Pharmacol. 2022;12:795078. doi:10.3389/fphar.2021.795078
   PubMed Web of Science ®Google Scholar
• Fonager K, Sørensen HT, Rasmussen SN, Møller-Petersen J, Vyberg M. Assessment of the diagnoses of Crohn’s disease and ulcerative colitis in a Danish hospital information system. Scand J Gastroenterol. 1996;31(2):154–159. doi:10.3109/00365529609031980
   PubMed Web of Science ®Google Scholar
• Schmidt M, Schmidt SAJ, Sandegaard JL, Ehrenstein V, Pedersen L, Sørensen HT. The Danish National Patient Registry: a review of content, data quality, and research potential. Clin Epidemiol. 2015;449–490. doi:10.2147/CLEP.S91125
   PubMed Web of Science ®Google Scholar
• Kissane J, Neutze JA, Singh H. Bowel Obstruction. In: Radiology Fundamentals. Springer International Publishing; 2020:187–193. doi:10.1007/978-3-030-22173-7_28
   Google Scholar
• Mizushima T, Kameyama H, Watanabe K, et al. Risk factors of small bowel obstruction following total proctocolectomy and ileal pouch anal anastomosis with diverting loop‐ileostomy for ulcerative colitis. Ann Gastroenterol Surg. 2017;1(2):122–128. doi:10.1002/ags3.12017
   PubMed Web of Science ®Google Scholar
• Dolejs S, Kennedy G, Heise CP. Small Bowel Obstruction Following Restorative Proctocolectomy: affected by a Laparoscopic Approach? J Surg Res. 2011;170(2):202–208. doi:10.1016/j.jss.2011.03.004
   PubMed Web of Science ®Google Scholar
• Lo B, Vind I, Vester-Andersen MK, Burisch J. Validation of ulcerative colitis and Crohn’s disease and their phenotypes in the Danish National Patient Registry using a population-based cohort. Scand J Gastroenterol. 2020;55(10):1171–1175. doi:10.1080/00365521.2020.1807598
   PubMed Web of Science ®Google Scholar